FREQUENTLY ASKED QUESTIONS

Yes!! With the added value that the syndicate uses a nominee vehicle to pool investment and keep the cap table of the startups clean and simple!

Its members!! In addition, while the Medtech Syndicate is a club, it uses a nominee vehicle (a limited company) to pool its investments. This is a not-for-profit organization owned by the directors of the Syndicate, elected by the members.

Yes and no. We only accept individuals or organizations that are considered “sophisticated” investors… 

Investing in early-stage startups carries a unique set of challenges and isn’t suited for everyone. Although the prospect of significant returns is appealing, it’s crucial to recognize the inherent risks involved. These include the potential for complete investment loss, limited liquidity, ownership dilution, and the non-payment of dividends. Such factors make early-stage investing a high-risk, high-reward endeavor that requires careful consideration that is reviewed during the new member process.

No, we have various profiles of members. Some with strong medtech experiences, former founders or from large corporations, bringing technical and deal expertise to the syndicate, as well as some non-medtech members, bringing entrepreneurship, finance, or other expertise to the table. A member can be active, or passive, and we try to make the balance right to ensure we keep a dynamic club!

Non-medtech members will also learn the specificities of investing in the medtech sector, so this is a great opportunity to expand your investment knowledge and landscape!

Even if the Medtech Syndicate is not-for-profit, there are still expenses and charges required to sustain it (legal, compliance, accounting, administration, etc…). We also need to ensure the sustainability of the nominee vehicle to hold shares on behalf of its members. This is why the Medtech Syndicate has a comprehensive fee and pricing policy reviewed on an ongoing basis with the members: 

• Membership fee of €1,000 +VAT per year (prorata)
• Arrangement fees for each deal, depending on whether it is a new deal or a follow-on to an existing investment
• Placement fee for the company using the Medtech Syndicate to receive funding.

Yes, The Medtech Syndicate Nominee Ltd is registered as a TCSP with the Irish Department of Justice, to comply with Anti Money Laundering laws and regulations.

NOTE: The company is not regulated by the Central Bank of Ireland. Remember, we are a club of business angels!

Fill in the membership request form here, and we’ll contact you back within 10 working days!

If your application is approved, you will be required to sign the member declaration, read the syndicate charter explaining how we operate, and review the fee & pricing policies as well as the data privacy policy. Your membership will be complete once the membership fees are paid. You will then be included to our distribution list for on-going/new deals, be invited to or quarterly meeting, and have access to our member’s platform for document sharing and portfolio management.

At Medtech Syndicate, we ensure every member gets a look at the deal flow. Should a startup pique your interest, you have two ways to dive deeper: join a quarterly meeting live or remotely, or catch up with a recorded session at your convenience. 

Ready to move forward? We’ll unlock a trove of detailed startup documentation for you.

Decided to invest? Simply specify your interest as an investment amount. 

If you are interested to be a Deal Lead, we’ll work with you on it.

Once the Due Diligence is finalized, we ask your final investment amount and investment details for our solicitors to capture the necessary documents and receive the funds on their client account.
Once the deal concludes, we’ll let you know, issuing all the paperwork to complete your investment. Our methodical process guarantees transparency and smoothness for investors and startups alike during the investment journey.

As a member, how do I know how much I have invested and when/where?

The Medtech Syndicate uses a portfolio management tool called seraf-investor, a well-known tool within the business angel ecosystem. If you already are a user, you will be able to view all your investments under the same platform. If not, you will have a user ID as part of your membership, and will be able to access all your investments with the Medtech syndicate.

Each deal lead / syndicate representative provides an update during our quarterly meeting. It will be by email, as well as during the quarterly meeting (in person or remote), and recorded.

Investing in startups is fundamentally a long-haul commitment, demanding both patience and a deep understanding of the sector’s intricacies. Startups usually need more time to hit significant growth and maturity milestones compared to well-established companies. As a member of the Medtech Syndicate, acknowledging that exits could span several years is crucial. Our portfolio indicates that startups generally project an exit timeframe of 5 to 10 years.

Holding a long-term outlook is vital in the startup investment landscape, readying oneself for the diverse timelines exits might follow. While early-stage investments take time to mature and necessitate ongoing support, they hold the promise of substantial rewards upon successful exits. At the Medtech Syndicate, we commit to keeping you well-informed with regular updates and insights throughout your investment journey, ensuring you remain connected and engaged with this long-term endeavor.

If you want to apply, you need to have reached certain milestones in your new product/new technology. We always recommend aspiring founders to contact universities and their incubators to receive the best advice and access to subsidies to start their venture.

You would be ready to talk to us if you have reached the following milestones:

• A team (at least 2 people) are promoting this new ventures, with complementary skills (technical, business, etc…)
• The technology has been tested and shown it delivers on what is expected from it. Feedback from key opinion leaders or clinicians have been included in the development.
• The intellectual property has been identified and patent filed
• The market has been identified in its size, location and access (direct to patient, via clinicians, etc..)
• A clear knowledge of the regulatory pathway to reach the intended markets
• A clear understanding of the competitive landscape and alternative therapeutic areas
• A sound assessment of costs and prices, as well as reimbursement strategies
• Ideally, previous discussion with key strategic players in the intended markets, to understand if and how the technology would fit their business strategy.

You can always contact us at an earlier stage, and we will be delighted to meet and give advice, based on our availability!!